Name of Commentator:  Consultant Haematologist, Northern Trust on behalf of DHSSPSNI

Please state if, at any time, you have had any involvement with the health care industry or manufacturers (as listed in the list of stakeholders) in relation to the technology being appraised and have personally received payment or material benefit from that work. If so, please provide details including the date of your last involvement.

No, none.

Comments on Bortezomib Monotherapy for Relapsed Multiple Myeloma

I welcome the provisional recommendations of the ACD for Bortezomib. Use of Bortezomib as second line treatment will result in an initial increase in costs in Northern Ireland where it is currently used as a third line treatment. Bortezomib will be used earlier in the course of each patient's disease. We now need some estimate of what these costs might be for the myeloma population in N Ireland. I think the “rebate scheme” is a reasonable way to contain costs.